Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation

Documenti analoghi

• Blood biomarkers for Alzheimer's disease are correlated with treatment outcomes in a randomized trial assessing the effects of escitalopram on agitation
  di: Maansi Barnwal, et al.
  Pubblicazione: (2025)
• The I‐Learn Cognition and Behavior program for non‐pharmacological treatment of agitation in nursing home residents with neurocognitive disorders: A cluster randomized trial
  di: Céline Lourdel, et al.
  Pubblicazione: (2026)
• Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
  di: Valentina Di Caro, et al.
  Pubblicazione: (2025)
• The impact of estimated cardiorespiratory fitness on Alzheimer's disease biomarkers and their relationships with cognitive decline
  di: Adam J Paulsen, et al.
  Pubblicazione: (2025)
• Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
  di: Garrett B. Duncan, et al.
  Pubblicazione: (2025)